Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Sophie Mavrogeni ,
The treatment of vasculitides is mainly immunosuppressive, cardiac medication including b-blocker, ACE-inhibitors, diuretics, antithrombotic, antiarrhythmic drugs and even pacemaker implantation should also be considered accordingly. Cardiologists in close collaboration with rheumatologists should be on alert about the importance of cardiac involvement in vasculitides, in order to early identify and treat these patients before severe complications take place.
Necrotizing vasculitides are classified according to the predominant type of affected vessels.
(1). They share several clinical and pathologic features, as well as the association with the presence of serum antineutrophil cytoplasmic antibodies (ANCA) (1, 2), whereas it is unusual in PAN (2). Classification of systemic necrotizing vasculitides was established at the Chapel Hill Consensus Conference (3).
ANCA-associated vasculitides are characterised by the involvement of small vessels in various organs, including lungs, kidneys, skin and peripheral nervous system (1-2). Systemic symptoms are present in at least 50% of all patients in MPA and PAN.
Clinically significant cardiac involvement is a rare complication in systemic vasculitides, but it can be life-threatening (2). As many cardiac manifestations are clinically silent at least during their early stages, heart function should be systematically evaluated by ECG and echocardiography. If symptoms appear and the basic investigation is normal, further evaluation using cardiovascular magnetic resonance is of great value, because it is the ideal technique to reveal the presence of myocardial inflammation. Every cardiac tissue from myocardium to epicardium, endocardium, conduction system and coronary arteries may be affected by vasculitides. However cardiovascular manifestations due to vasculitides must be distinguished from those that can arise as a consequence of treatment with corticosteroids and immunosuppresants. Myocarditis due to vasculitis varies widely from 25 to 70% of cases. It is due to necrotizing vasculitis, presence of granulomas or fibrosis. In CSS, infiltration by eosinophils is considered as a possible cause and cardiac magnetic resonance (CMR) is of value for early detection of myocardial inflammation, especially in patients with atypical presentation (4). In KD it can be identified in almost half of patients. Coronary artery involvement can be detected, due to coronary arteritis that causes thromboses, dissections, stenosis and possible myocardial infarction. Coronary involvement was documented in 50% of PAN. It is also very common in KD (20% of untreated cases) and can be easily diagnosed by both echocardiography and CMR (5). CMR is also of value for myocardial infarction detection and coronary arteries evaluation (6). Pericardial involvement was documented in 22% of CSS, 8% of WG and 0-27% of PAN and it can contribute to constrictive pericarditis, if left untreated. Endocardium involvement is rather unusual, but it can promote valve distortion in some cases. Arrhythmias (mainly supraventricular), AV or bundle branch block can also be found due to myocarditis, ischemia or heart failure (2). Pulmonary hypertension is a rare complication in vasculitides.
The treatment is mainly immunosuppressive, cardiac medication including b-blocker, ACE-inhibitors, diuretics, antithrombotic, antiarrhythmic drugs and even pacemaker implantation should also be considered accordingly. Cardiologists in close collaboration with rheumatologists should be on alert about the importance of cardiac involvement in vasculitides, in order to early identify and treat these patients before severe complications take place.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Boki KA, Dafni U, Karpouzas GA, Papasteriades C, Drosos AA, Moutsopoulos HM. Necrotizing vasculitis in Greece: clinical, immunological and immunogenetic aspects. A study of 66 patients. Br J Rheumatol 1997; 36(10): 1059-66 2. Pagnoux C, Guillevin L. Cardiac involvement in small and medium-sized vessel vasculitides. Lupus 2005; 14:1-5 3. Sorensen SF, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in a five-year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000; 59: 478-482 4. Mavrogeni S, Tsirogianni AK, Gialafos EJ, Manoussakis MN. Detection of myocardial inflammation by contrast-enhanced MRI in a patient with Churg-Strauss syndrome. Int J Cardiol 2007 Aug 17: (Epub ahead of print) 5. Mavrogeni S, Papadopoulos G et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol. 2004 Feb 18; 43(4):649-52. 6. Mavrogeni S, Papadopoulos G, Douskou M, Kaklis S, Seimenis I, Varlamis G, Karanasios E, Krikos X, Giannoulia A, Cokkinos DV. Magnetic resonance angiography, function and viability evaluation in patients with Kawasaki disease. J Cardiovasc Magn Reson. 2006; 8(3):493-8.
Dr S. Mavrogeni MD, FESC, Onassis Cardiac Surgery Center Athens, Greece Nucleus Member of the ESC WG for Cardiovasular Magnetic Resonance
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved